2. Search Result
Search Result
Results for "

cytotoxic therapy

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dyes

3

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

2

Natural
Products

1

Click Chemistry

3

GMP Molecules

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-P99144A
    Anti-Mouse PD-1 Antibody (S-5001)
    1 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .
    Anti-Mouse PD-1 Antibody (S-5001)
  • HY-163028
    ML-T7

    		Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-T7
  • HY-P99916
    Emirodatamab

    AMG-427

    		 FLT3 CD3 TNF Receptor Inflammation/Immunology Cancer
    Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
    Emirodatamab
  • HY-P10239
    Tyr3-Octreotate

    		Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [ 111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [ 90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .
    Tyr3-Octreotate
  • HY-15579G
    MMAF

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
    MMAF
  • HY-151486
    GLUT1-IN-1

    		GLUT Cancer
    GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer .
    GLUT1-IN-1
  • HY-W127820
    H2TMpyP-2 chloride

    Tetrakis(2-N-methylpyridyl)porphine chloride

    		 Biochemical Assay Reagents Fluorescent Dye Others
    H2TMpyP-2 (tetrakis(2-N-methylpyridyl)porphine) chloride is an active photosensitizer with strong absorption properties in the visible to near-infrared region and excellent singlet oxygen quantum yield. Captisol-TMPyP complexes can be used in supramolecular nanosynthesis to increase singlet oxygen production, improve photostability and better photosensitization, and support photodynamic therapy activity. The Captisol:TMPyP complex also exhibited antibacterial activity against Escherichia coli and was cytotoxic against lung cancer A549 cells .
    H2TMpyP-2 chloride
  • HY-175020
    QNX-10

    		Fatty Acid Synthase (FASN) Apoptosis Bcl-2 Family Cancer
    QNX-10 is a fatty acid synthase (FASN) inhibitor (IC50 = 0.7 μM) with anticancer activity. QNX-10 exhibits potent FASN inhibition and cytotoxicity against colorectal and breast cancer cells. QNX-10 induces apoptosis and cell cycle arrest in S phase by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-xL. QNX-10 can be used to investigate anticancer therapies targeting FASN enzymes .
    QNX-10
  • HY-175673
    LCB-2151

    		Carnitine Palmitoyltransferase (CPT) Apoptosis Oxidative Phosphorylation Mitochondrial Metabolism Reactive Oxygen Species (ROS) Cancer
    LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research .
    LCB-2151
  • HY-178275
    Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol

    		Drug-Linker Conjugates for ADC Cancer
    Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol (Example 9) is a conjugate of the ADC toxic molecule and the linker, where the toxic molecule part is Hydrotecan (HY-164378), and the linker part is Mc-Glu(D-Glucamine)-val-ala (HY-178309) .
    Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol
  • HY-174212
    MXC-017

    		Apoptosis Cancer
    MXC-017 is a blood-brain barrier (BBB)-penetrant apoptosis inducer that directly targets Vimentin (VIM). MXC-017 prevents radiation-induced glioma stem cell (GSC) formation, while promoting G0/G1 cell cycle arrest and apoptosis. MXC-017 exhibits minimal off-target effects and shows no significant cytotoxicity. MXC-017 significantly prolongs median survival when used in combination with radiation therapy in glioblastoma (GBM) mouse models.
    MXC-017
  • HY-13644
    Gusperimus

    15-Deoxyspergualin

    		 Others Others
    Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.
    Gusperimus
  • HY-179560
    PMV6-PEG4-BI2536

    		Polo-like Kinase (PLK) MDM-2/p53 Cancer
    PMV6-PEG4-BI2536 is a p53-Y220C-PLK1 dual-functional compound, composed of a high-affinity p53-Y220C mutant binder (Kd ≈ 2.5 nM) and a potent PLK1 kinase inhibitor (IC50 = 0.83 nM). PMV6-PEG4-BI2536 triggers TP53 Y220C cell G2/M arrest and apoptosis through PLK1 mislocalization and kinase inhibition, independent of p53 transcriptional reactivation. PMV6-PEG4-BI2536 can be used for the study of TP53 mutant cancers .
    PMV6-PEG4-BI2536
  • HY-128952G
    Tesirine

    SG3249

    		 Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker Cancer
    Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
    Tesirine
  • HY-N15346
    Menominin B

    		Others Cancer
    Menominin B is a cyclic peptide found in the freshwater sponge-associated cyanobacterium Nostoc sp. with cytotoxic properties. Menominin B exhibits antiproliferative activity against the ovarian cancer cell line OVCAR3 (with IC50 of 2.4 μM). Menominin B holds promise for research in the field of anticancer therapy .
    Menominin B
  • HY-106072
    Vinzolidine

    LY 104208

    		 Microtubule/Tubulin Cancer
    Vinzolidine is a semisynthetic derivative of the catharanthus alkaloid. Vinzolidine exerts its cytotoxic effect on tumor cells by interfering with microtubulin polymerization, thereby inhibiting cell division. Vinzolidine can be utilized in research to investigate synergistic effects when combined with other chemotherapeutic agents or biologic therapies, as well as to study cancer cells' tolerance or resistance to these treatments, and to explore approaches to overcome such obstacles .
    Vinzolidine
  • HY-172153
    CDK2-IN-41

    		CDK Reactive Oxygen Species (ROS) Apoptosis Cancer
    CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .
    CDK2-IN-41
  • HY-169122
    LLC1

    		Drug Derivative Cancer
    LLC1 is an Amiloride (HY-B0285) derivative with cytotoxicity against breast cancer cells, particularly those resistant to treatment. The IC50 values of LLC1 for MCF7, MCF7 MX-100, MCF7 TS, MCF7 TR-1, and MCF7 TR-5 are 13, 12, 25, 26, and 19 mM, respectively. LLC1 shows potential for research in the field of cancer therapy .
    LLC1
  • HY-161668
    Ru-Poma

    		Ligands for E3 Ligase Ferroptosis Cancer
    Ru-Poma is a Ru(II)-based photosensitizer, which attenuates Cisplatin (HY-17394)-resistant tumor through photodynamic therapy (PDT). Ru-Poma photodegrades CRBN through a Pomalidomide (HY-10984) moiety. Ru-Poma induces ferroptosis, through an increase in lipid peroxide, downregulation of GPX4 and GAPDH expression. Ru-Poma exhibits cytotoxicity in A549, with IC50 of 18.46 μM and 0.37 μM in dark and upon irradiation, respectively .
    Ru-Poma
  • HY-121642
    SL-017

    		Others Others
    SL-017 is a novel photoacoustic sensitizer and a derivative of photofrin B. It can be taken up by cells to the maximum extent within 30 minutes and is mainly localized in mitochondria. After being activated by visible light or ultrasound, SL-017 can significantly increase the production of reactive oxygen species (ROS). Low concentrations of SL-017 can rapidly cause the loss of mitochondrial membrane potential. SL-017 can also cause mitochondrial fragmentation, a process that occurs after the loss of membrane potential. Epoxyeicosatrienoic acids (EETs) can alleviate the loss of mitochondrial membrane potential caused by SL-017, but the antioxidant ascorbic acid has no such effect. These characteristics indicate that SL-017 mainly targets mitochondria and exerts its cytotoxic effect by triggering the collapse of mitochondrial membrane potential, generating ROS, and causing mitochondrial fragmentation. As a novel photoacoustic sensitizer, SL-017 has potential application value in photodynamic therapy and sonodynamic therapy.
    SL-017
  • HY-159921
    Tubulin Polymerization-IN-1 prodrug

    		Microtubule/Tubulin Cancer
    Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
    Tubulin Polymerization-IN-1 prodrug
  • HY-126161
    Nonabine

    BRL-4664

    		 Cannabinoid Receptor Neurological Disease Cancer
    Nonabine (BRL-4664) is an orally active chromenol derivative and Cannabinoid-like antiemetic. Nonabine controls nausea and vomiting induced by cancer chemotherapy regimens. Nonabine can be used in the research of lymphoma and chemotherapy-induced nausea and vomiting .
    Nonabine
  • HY-P990716
    Sabestomig

    AZD7789

    		 PD-1/PD-L1 Tim3 Inflammation/Immunology
    Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .
    Sabestomig
  • HY-N15348
    Aphidicolins B32

    		Others Cancer
    Aphidicolins B32 is a diterpenoid compound discovered in the marine fungus Botryotinia fuckeliana, exhibiting cytotoxic activity against human bladder cancer cells. It inhibits the proliferation of T24 cells in the G0/G1 phase, with an IC50 of 27.6 μM. Aphidicolins B32 holds potential for research in the field of cancer therapy .
    Aphidicolins B32
  • HY-W094745
    5,10,15,20-Tetrakis(4-chlorophenyl)porphyrin

    		MOFs Photosensitizer Inflammation/Immunology
    5,10,15,20-Tetrakis(4-chlorophenyl)porphyrin (Compound 5) is a photosensitizer. 5,10,15,20-Tetrakis(4-chlorophenyl)porphyrin shows no significant photodynamic cytotoxicity. 5,10,15,20-Tetrakis(4-chlorophenyl)porphyrin is mainly used for the optimization of photosensitizer structure in photodynamic therapy (PDT) for psoriasis .
    5,10,15,20-Tetrakis(4-chlorophenyl)porphyrin
  • HY-180169
    Photosensitizer-8

    		Photosensitizer Drug Derivative Cancer
    Photosensitizer-8 (Compound 4), 2-anthrol derivative, is an alkaline phosphatase (ALP)-activatable photosensitizer. Photosensitizer-8 undergoes a phosphate ester hydrolysis reaction in the presence of ALP, rapidly converting into the active photosensitizer 2-anthrol. Photosensitizer-8 exhibits cytotoxicity against ALP-overexpressing cancer cells (HeLa, A549, HCT116) after light exposure, with IC50 values of 14.3 μM, 21.6 μM and 17.5 μM, respectively, while showing no significant cytotoxicity against normal lung fibroblasts (WI-38) (IC50 ≥ 30 μM). Photosensitizer-8 can be used in photodynamic therapy research for ALP-overexpression-related cancers .
    Photosensitizer-8
  • HY-181879
    PROTAC mHTT Degrader-1

    		PROTACs Huntingtin Neurological Disease
    PROTAC mHTT Degrader-1 is a blood-brain barrier-penetrant mutant huntingtin (mHTT) PROTAC degrader. PROTAC mHTT Degrader-1 specifically recognizes pathogenic mHTT aggregates and recruits Cereblon (CRBN), thereby inducing ubiquitination and proteasomal degradation of mHTT. PROTAC mHTT Degrader-1 alleviates mHTT-induced cytotoxicity and neuroinflammation. In the R6/2 Huntington's disease mouse model, PROTAC mHTT Degrader-1 reduces cerebral protein aggregation levels and improves body weight, motor coordination and survival rate of animals. PROTAC mHTT Degrader-1 can be used for research on PROTAC therapies for Huntington's disease and other neurodegenerative diseases .
    PROTAC mHTT Degrader-1
  • HY-15947G
    Ravoxertinib

    GDC-0994

    		 ERK c-Myc Hexokinase Lactate Dehydrogenase Cancer
    Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
    Ravoxertinib
  • HY-181413
    PROTAC EZH2 Degrader-44

    		PROTACs Histone Methyltransferase Bcl-2 Family Caspase PARP Cancer
    PROTAC EZH2 Degrader-44 (compound 60) is a highly efficient PROTAC degrader targeting the EZH2-PRC2 complex. By recruiting the CRBN E3 ligase and relying on the proteasome system, PROTAC EZH2 Degrader-44 simultaneously induces the degradation of core components EZH2, SUZ12 and EED, thereby significantly reducing the levels of H3K27me3 and CARM1. PROTAC EZH2 Degrader-44 exerts antiproliferative effects through a dual mechanism: on the one hand, it triggers mitochondrial dysfunction leading to decreased membrane potential; on the other hand, it strongly promotes apoptosis by regulating Bcl-2 family proteins (upregulating Bax, Caspase-3 and PARP, and downregulating Bcl-2). PROTAC EZH2 Degrader-44 exhibits only extremely low cytotoxicity in human normal mammary epithelial, liver and kidney cells, showing a favorable safety window. PROTAC EZH2 Degrader-44 is an ideal tool molecule for exploring the mechanisms of targeted therapy for triple-negative breast cancer .
    PROTAC EZH2 Degrader-44

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: